BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Angiogenesis and Vasculogenic Mimicry as Therapeutic Targets in Ovarian Cancer
Dansaem Lim1 (Graduate student), Yeojin Do1 (Graduate student), Byung Su Kwon1 (Research worker), Woochul Chang1 (Research worker), Myeong-Sok Lee1 (Research worker), Jongmin Kim 1 (Associate Professor), Jin Gu Cho1,* (Research Professor)
1Division of Biological Sciences, Sookmyung Women’s University, Seoul, 04310, Korea,
2Research Institute for Women's Health, Sookmyung Women's University, Seoul, Republic of Korea,
3Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea,
4Department of Biology Education, College of Education, Pusan National University, Busan, 46241, Korea
Tumor angiogenesis is an essential process for growth and metastasis of cancer cells as it supplies tumors with oxygen and nutrients. During tumor angiogenesis, many pro-angiogenic factors are secreted by tumor cells to induce their own vascularization via activation of pre-existing host endothelium. However, accumulating evidence suggests that vasculogenic mimicry (VM) is a key alternative mechanism for tumor vascularization when tumors are faced with insufficient supply of oxygen and nutrients. VM is a tumor vascularization mechanism in which tumors create a blood supply system, in contrast to tumor angiogenesis mechanisms that depend on pre-existing host endothelium. VM is closely associated with tumor progression and poor prognosis in many cancers. Therefore, inhibition of VM may be a promising therapeutic strategy and may overcome the limitations of anti-angiogenesis therapy for cancer patients. In this review, we provide an overview of the current anti-angiogenic therapies for ovarian cancer and the current state of knowledge regarding the links between microRNAs and the VM process, with a focus on the mechanism that regulates associated signaling pathways in ovarian cancer. Moreover, we discuss the potential for VM as a therapeutic strategy against ovarian cancer.
Abstract, Accepted Manuscript [Submitted on March 20, 2020, Accepted on May 13, 2020]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd